// startup autopsy
Zymergen
Synthetic biology company raised over 800 million dollars and IPO at 3.8 billion before revealing its flagship product was commercially useless just two months after going public.
marketfitSudden Collapse
Unexpected shutdown within weeks of a trigger · Fatal mistake: No Product Market Fit
// the model, blind
Evaluating only Zymergen’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: No market fit.
Key Events Timeline
FOUNDING
Zymergen founded in Emeryville, California to use machine learning and robotic automation to engineer microbes for industrial manufacturing.
FOUNDING
Zymergen founded
FUNDING
Raised 400 million dollar Series C led by SoftBank to build out robotics lab infrastructure and advance product pipeline toward commercial scale.
PRODUCT LAUNCH
Zymergen IPO raised 528 million dollars at 3.8 billion dollar valuation on Nasdaq; stock opened 25 percent above offer price on strong investor enthusiasm.
ACQUISITION ATTEMPT
Ginkgo Bioworks acquired Zymergen in an all-stock rescue deal valued at approximately 300 million dollars; a more than 90 percent decline from the IPO valuation.